|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
OR_on1061865433 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr ||||||||||| |
008 |
181105s2019 nju ob 001 0 eng |
010 |
|
|
|a 2018053075
|
040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d DG1
|d YDX
|d N$T
|d EBLCP
|d OCLCF
|d UAB
|d CHVBK
|d MERER
|d DLC
|d OCLCO
|d OCLCA
|d OCLCO
|d K6U
|d OCL
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1086209622
|
020 |
|
|
|a 9781119289210
|q (Adobe PDF)
|
020 |
|
|
|a 1119289211
|
020 |
|
|
|a 9781119289227
|q (ePub)
|
020 |
|
|
|a 111928922X
|
020 |
|
|
|z 9781119289197
|q (hardback)
|
020 |
|
|
|a 9781119289234
|q (electronic bk. ;
|q oBook)
|
020 |
|
|
|a 1119289238
|q (electronic bk. ;
|q oBook)
|
029 |
1 |
|
|a CHVBK
|b 559026838
|
029 |
1 |
|
|a CHNEW
|b 001039220
|
029 |
1 |
|
|a AU@
|b 000065193807
|
035 |
|
|
|a (OCoLC)1061865433
|z (OCoLC)1086209622
|
042 |
|
|
|a pcc
|
050 |
1 |
0 |
|a RC600
|
060 |
1 |
0 |
|a WD 305
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
0 |
|a 616.97/806
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Quantitative pharmacology and individualized therapy strategies in development of therapeutic proteins for immune-mediated inflammatory diseases /
|c edited by Honghui Zhou, Diane R. Mould.
|
264 |
|
1 |
|a Hoboken, NJ :
|b Wiley,
|c 2019.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
500 |
|
|
|a "John Wiley & Sons Inc."--tp verso.
|
504 |
|
|
|a Includes bibliographical references and index.
|
520 |
|
|
|a "Focused on quantitative pharmacology and individualized therapy for developing biotherapeutics in immune-mediated inflammatory diseases, this book discusses both theoretical and practical aspects and includes case studies illustrating applications in drug development. Provides frontline knowledge of using PK/PD modeling tools to address a variety of problems in development of therapeutic proteins. Reviews and discusses biomarkers, systems pharmacology, PBPK modeling, and target-mediated modeling, as translational tools. Helps readers understand disease progression and identify of mechanisms-based biomarkers with clinical relevance"--Provided by publisher.
|
588 |
|
|
|a Description based on print version record and CIP data provided by publisher.
|
505 |
0 |
|
|a Disease Interception in Autoimmune Diseases: From a Conceptual Framework to Practical Implementation / Anish Suri -- The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC) / Reena Khanna, Brian G Feagan -- Mechanism and Physiologically Based PK/PD Model in Assisting Translation from Preclinical to Clinical: Understanding PK/PD of Therapeutic Proteins at Site-of-Action / Xi Chen, Weirong Wang -- Application of Minimal Anticipated Biological Effect Level (MABEL) in Human Starting Dose Selection for Immunomodulatory Protein Therapeutics -- Principles and Case Studies / Haiqing Wang, Zheng Yang, Rong Shi -- Model-Based Meta-Analysis Use in the Development of Therapeutic Proteins / Timothy J Taylor, Bill Frame, Angela D Taylor -- Utility of Joint Population Exposure-Response Modeling Approach to Assess Multiple Continuous and Categorical Endpoints in Immunology Drug Development / Chuanpu Hu, Honghui Zhou -- Modeling Approaches to Characterize Target-Mediated Pharmacokinetics and Pharmacodynamics for Therapeutic Proteins / Leonid Gibiansky, Ekaterina Gibiansky -- Tutorial: Numerical (NONMEM) Implementation of the Target-Mediated Drug Disposition Model / Leonid Gibiansky, Ekaterina Gibiansky -- Translational Considerations in Developing Bispecific Antibodies: What Can We Learn from Quantitative Pharmacology? / Pradeep B Lukka, Santosh Wagh, Bernd Meibohm -- Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases / Sihem Ait-Oudhia, Yi Ting (Kayla) Lien, Sumit Basu, Lawrence Lesko, Stephan Schmidt -- Pharmacokinetics-Based Dosing for Therapeutic Monoclonal Antibodies in Inflammatory Bowel Disease / Niels Vande Casteele, William J Sandborn -- Pharmacokinetics-Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease / Diane R Mould, Richard N Upton, Jessica Wojciechowski -- Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects -- Some Considerations / Deni Hardiansyah, Chee M Ng -- Quantitative Pharmacology Assessment Strategy Therapeutic Proteins in Pediatric Subjects -- Challenges and Opportunities / Jeremiah D Momper, Andrew Mulberg, Nitin Mehrotra, Dan Turner, William Faubion, Laurie Conklin, Karim Azer, Marla C Dubinsky -- Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins for Plaque Psoriasis -- Guselkumab / Zhenling Yao, Yaowei Zhu, Chuanpu Hu, Yang Chen, Shu Li, Bruce Randazzo, Zhenhua Xu, Amarnath Sharma, Honghui Zhou -- Vedolizumab-A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease / Maria Rosario, Nathanael L Dirks, Diane R Mould, Catherine Scholz, Timothy Wyant, Asit Parikh, Irving Fox -- Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Systemic Lupus Erythematosus -- Belimumab / Herbert Struemper -- Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis -- Peginterferon Beta-1a, Daclizumab Beta, Natalizumab / Xiao Hu, Yaming Hang, Lei Diao, Kumar K Muralidharan, Ivan Nestorov -- Index -- Supplemental Images.
|
590 |
|
|
|a O'Reilly
|b O'Reilly Online Learning: Academic/Public Library Edition
|
650 |
|
0 |
|a Immunologic diseases
|x Treatment.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
|
0 |
|a Mathematical models.
|
650 |
1 |
2 |
|a Autoimmune Diseases
|x drug therapy
|
650 |
1 |
2 |
|a Proteins
|x therapeutic use
|
650 |
2 |
2 |
|a Proteins
|x pharmacokinetics
|
650 |
2 |
2 |
|a Protein Engineering
|x methods
|
650 |
2 |
2 |
|a Models, Theoretical
|
650 |
|
2 |
|a Pharmacology
|
650 |
|
6 |
|a Maladies immunologiques
|x Traitement.
|
650 |
|
6 |
|a Pharmacologie.
|
650 |
|
6 |
|a Modèles mathématiques.
|
650 |
|
7 |
|a pharmacology.
|2 aat
|
650 |
|
7 |
|a mathematical models.
|2 aat
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Mathematical models
|2 fast
|
650 |
|
7 |
|a Immunologic diseases
|x Treatment
|2 fast
|
650 |
|
7 |
|a Pharmacology
|2 fast
|
700 |
1 |
|
|a Zhou, Honghui,
|e editor.
|
700 |
1 |
|
|a Mould, Diane R.
|q (Diane Renee),
|d 1960-
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Quantitative pharmacology and individualized therapy strategies in development of therapeutic proteins for immune-mediated inflammatory diseases
|b First edition.
|d Hoboken, NJ : Wiley, [2019]
|z 9781119289197
|w (DLC) 2018051418
|
856 |
4 |
0 |
|u https://learning.oreilly.com/library/view/~/9781119289197/?ar
|z Texto completo (Requiere registro previo con correo institucional)
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 16080648
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 16055307
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 2030089
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL5709855
|
994 |
|
|
|a 92
|b IZTAP
|